查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1288788

全球流感疫苗市場研究報告 - 行業分析、規模、佔有率、成長、趨勢和2023至2030年預測

Global Influenza Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 289 Pages | 商品交期: 最快1-2個工作天內

價格

到2030年，全球對流感疫苗的需求將從2022年的10.5BN美元達到近26.751BN美元的市場規模，在2023-2030年的研究期間，複合年成長率為10.95%。

流感疫苗是一種可以預防流感的疫苗，流感是一種由流感病毒引起的高度傳染性呼吸道疾病。疫苗通過促使身體的免疫系統釋放可以識別和抵抗流感病毒的抗體來起作用。流感疫苗通常每年接種一次，通常在流感季節開始之前的秋季或冬季。該疫苗通常推薦給六個月以上的每個人，特別是發生流感嚴重併發症風險較高的人，如老年人、患有基礎疾病的人和孕婦。

市場動態：

流感的高流行率是流感疫苗市場的主要驅動力之一。流感是一種高度傳染性的呼吸道疾病，可導致嚴重併發症，特別是在高危人群（老年人和患有基礎疾病的人）中。世界各國政府已發起舉措，以提高疫苗接種率並減輕流感對醫療保健系統的負擔。這些舉措提高了對流感疫苗益處的認識，並增加了對疫苗的需求。疫苗技術的進步使生產和分發流感疫苗變得更加容易。與傳統的雞蛋疫苗相比，較新的疫苗技術，如重組DNA和基於細胞的疫苗，具有多種優勢，例如更快的生產時間和更高的功效。發達國家和發展中國家的醫療保健支出增加正在推動流感疫苗市場的增長。政府和私人醫療保健提供者正在投資疫苗接種等預防措施，以減輕醫療保健系統的整體負擔。不斷增長的老年人口是流感疫苗市場的主要驅動力，因為老年人患流感嚴重併發症的風險更高。

該研究報告涵蓋了波特的五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清楚地瞭解行業結構，並在全球範圍內評估競爭吸引力。此外，這些工具還對全球流感疫苗市場的每個市場區隔進行了包容性評估。流感疫苗行業的增長和趨勢為這項研究提供了整體方法。

區域分析：

這一部分涵蓋了區域前景，強調了北美、歐洲、亞太、拉美、中東和非洲的流感疫苗市場的當前和未來需求。此外，該報告重點關注所有突出地區的個別應用部門的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況和對全球競爭格局的深入看法。流感疫苗市場的主要參與者包括GSK plc, AstraZeneca, SINOVAC, Pfizer Inc, Vaxess Technologies Inc, CSL Limited, EMERGENT, Merck & Co., Inc., Viatris Inc., OSIVAX, EMERGEX VACCINES。這一部分包括對競爭格局的整體看法，其中包括各種戰略發展，如主要的合併和收購、未來的能力、夥伴關係、財務概況、合作、新產品的開發、新產品的推出以及其他發展。

目錄

第1章：前言

  • 報告描述
    • 目的
    • 目標受眾
    • 獨特的銷售主張（USP）和產品
  • 研究範圍
  • 研究方法
    • 市場研究過程
    • 市場研究方法

第二章：執行摘要

  • 市場的亮點
  • 全球市場簡介

第三章：流感疫苗- 行業分析

  • 簡介- 市場動態
  • 市場驅動力
  • 市場限制因素
  • 機會
  • 行業趨勢
  • 波特的五力分析
  • 市場吸引力分析
    • 市場吸引力分析（按疫苗類型
    • 市場吸引力分析（按適應症分類
    • 按年齡組分類的市場吸引力分析
    • 按給藥途徑分類的市場吸引力分析
    • 按銷售管道分類的市場吸引力分析
    • 市場吸引力分析：按地區

第四章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料製造商名單
    • 關鍵原料的價格趨勢
  • 潛在買家名單
  • 行銷管道
    • 直接行銷
    • 間接行銷
    • 行銷管道的發展趨勢

第五章：Covid-19疫情的影響分析

第六章：全球流感疫苗市場分析：按疫苗類型分類

  • 按疫苗類型概述
  • 歷史和預測數據
  • 按疫苗類型分析
  • 去活化疫苗
  • 減毒活疫苗

第7章：全球流感疫苗市場分析：按適應症分類

  • 適應症概述
  • 歷史和預測數據
  • 按適應症分析
  • 四價
  • 三價

第八章：全球流感疫苗市場分析：按年齡組分類

  • 按年齡組概述
  • 歷史和預測數據
  • 按年齡組分析
  • 兒科
  • 成人

第九章：全球流感疫苗市場分析：按給藥途徑分類

  • 按給藥途徑的概述
  • 歷史和預測數據
  • 按給藥途徑的分析
  • 注射劑
  • 鼻腔噴霧劑

第十章：全球流感疫苗市場分析：按配銷通路分類

  • 配銷通路概述
  • 歷史和預測數據
  • 按配銷通路的分析
  • 醫院和藥店
  • 政府和機構供應
  • 其他管道

第11章：全球流感疫苗市場分析：按地理區域分類

  • 頂級公司佔有率分析
  • 簡介
  • 北美地區銷售分析
    • 概述，歷史和預測的銷售分析
    • 北美地區分部銷售分析
    • 北美洲國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概況、歷史和預測的銷售分析
    • 歐洲分部銷售分析
    • 歐洲國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概況、歷史和預測的銷售分析
    • 亞太地區分部銷售分析
    • 亞太地區國家銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳大利亞銷售分析
    • 亞太其他地區銷售分析
  • 拉美地區銷售分析
    • 概況、歷史和預測的銷售分析
    • 拉美地區分部銷售分析
    • 拉美地區國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概況、歷史和預測銷售分析
    • 中東和非洲地區分部銷售分析
    • 中東和非洲國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 其他中東和非洲國家銷售分析

第十二章：流感疫苗公司的競爭格局

  • 流感疫苗市場競爭
  • 夥伴關係/合作/協議
  • 合併和收購
  • 新產品發布
  • 其他方面的發展

第十三章：公司簡介

  • 公司佔有率分析
  • 市場集中度
  • GSK plc
    • 公司概況
    • 公司收入
    • 產品
    • 近期發展
  • AstraZeneca
    • 公司概況
    • 公司收入
    • 產品
    • 近期發展
  • SINOVAC
    • 公司概覽
    • 公司收入
    • 產品
    • 近期發展
  • Pfizer Inc
    • 公司概覽
    • 公司收入
    • 產品
    • 近期發展
  • Vaxess Technologies Inc
    • 公司概覽
    • 公司收入
    • 產品
    • 近期發展
  • CSL Limited
    • 公司概覽
    • 公司收入
    • 產品
    • 近期發展
  • EMERGENT
    • 公司概覽
    • 公司收入
    • 產品
    • 近期發展
  • Merck & Co. Inc.
    • 公司概覽
    • 公司收入
    • 產品
    • 近期發展
  • Viatris Inc.
    • 公司概覽
    • 公司收入
    • 產品
    • 近期發展
  • OSIVAX
    • 公司概覽
    • 公司收入
    • 產品
    • 近期發展
  • EMERGEX VACCINES
    • 公司概覽
    • 公司收入
    • 產品
    • 近期發展情況

注意- 在公司簡介中，財務細節和最近的發展情況取決於可用性，可能不包括私人公司在內。

Product Code: VMR112110532

The global demand for Influenza Vaccine Market is presumed to reach the market size of nearly USD 26.751 BN by 2030 from USD 10.5 BN in 2022 with a CAGR of 10.95% under the study period 2023-2030.

Influenza vaccine, or flu shot, is a vaccine that protects against influenza, a highly contagious respiratory illness caused by influenza viruses. The vaccine works by prompting the body's immune system to release antibodies that can recognize and fight off the influenza virus. The influenza vaccine is typically given once a year, usually in the fall or winter, before the flu season begins. The vaccine is usually recommended for everyone over the age of six months, particularly individuals at higher risk of developing severe complications from influenza, such as the elderly, individuals with underlying medical conditions, and pregnant women.

Market Dynamics:

The high prevalence of influenza is one of the primary drivers of the influenza vaccine market. Influenza is a highly contagious respiratory illness that can lead to severe complications, particularly in high-risk populations (elderly and individuals with underlying medical conditions). Governments around the world have launched initiatives to scale up vaccination rates and reduce the burden of influenza on healthcare systems. These initiatives have led to increased awareness about the benefits of the influenza vaccine and increased demand for the vaccine. Advances in vaccine technology have made it easier to produce and distribute the influenza vaccine. Newer vaccine technologies, such as recombinant DNA and cell-based vaccines, offer several advantages over traditional egg-based vaccines, such as faster production times and improved efficacy. Increasing healthcare spending in developed and developing countries is driving the growth of the influenza vaccine market. Governments and private healthcare providers are investing in preventative measures such as vaccination to reduce the overall burden on healthcare systems. The growing elderly population is a key driver of the influenza vaccine market, as elderly individuals are at higher risk of developing severe complications from influenza.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of influenza vaccine. The growth and trends of influenza vaccine industry provide a holistic approach to this study.

Market Segmentation:

This section of the influenza vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Vaccine Type

  • Inactivated
  • Live Attenuated

By Indication

  • Quadrivalent
  • Trivalent

By Age Group

  • Pediatric
  • Adult

By Route Of Administration

  • Injection
  • Nasal Spray

By Distribution Channel

  • Hospitals & Pharmacies
  • Government & Institutional Supply
  • Other

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Influenza Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the influenza vaccine market include GSK plc, AstraZeneca, SINOVAC, Pfizer Inc, Vaxess Technologies Inc, CSL Limited, EMERGENT, Merck & Co., Inc., Viatris Inc., OSIVAX, EMERGEX VACCINES. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . INFLUENZA VACCINE - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Vaccine Type
    • 3.7.2 Market Attractiveness Analysis By Indication
    • 3.7.3 Market Attractiveness Analysis By Age Group
    • 3.7.4 Market Attractiveness Analysis By Route Of Administration
    • 3.7.5 Market Attractiveness Analysis By Distribution Channel
    • 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY VACCINE TYPE

  • 6.1 Overview by Vaccine Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Vaccine Type
  • 6.4 Inactivated Historic and Forecast Sales by Regions
  • 6.5 Live Attenuated Historic and Forecast Sales by Regions

7 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY INDICATION

  • 7.1 Overview by Indication
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Indication
  • 7.4 Quadrivalent Historic and Forecast Sales by Regions
  • 7.5 Trivalent Historic and Forecast Sales by Regions

8 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY AGE GROUP

  • 8.1 Overview by Age Group
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Age Group
  • 8.4 Pediatric Historic and Forecast Sales by Regions
  • 8.5 Adult Historic and Forecast Sales by Regions

9 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 9.1 Overview by Route Of Administration
  • 9.2 Historical and Forecast Data
  • 9.3 Analysis by Route Of Administration
  • 9.4 Injection Historic and Forecast Sales by Regions
  • 9.5 Nasal Spray Historic and Forecast Sales by Regions

10 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 10.1 Overview by Distribution Channel
  • 10.2 Historical and Forecast Data
  • 10.3 Analysis by Distribution Channel
  • 10.4 Hospitals & Pharmacies Historic and Forecast Sales by Regions
  • 10.5 Government & Institutional Supply Historic and Forecast Sales by Regions
  • 10.6 Other Historic and Forecast Sales by Regions

11 . GLOBAL INFLUENZA VACCINE MARKET ANALYSIS BY GEOGRAPHY

  • 11.1. Top Company Share Analysis
  • 11.2. Introduction
  • 11.3. North America Sales Analysis
    • 11.3.1. Overview, Historic and Forecast Sales Analysis
    • 11.3.2. North America By Segment Sales Analysis
    • 11.3.3. North America By Country Sales Analysis
    • 11.3.4. United State Sales Analysis
    • 11.3.5. Canada Sales Analysis
    • 11.3.6. Mexico Sales Analysis
  • 11.4. Europe Sales Analysis
    • 11.4.1. Overview, Historic and Forecast Sales Analysis
    • 11.4.2. Europe by Segment Sales Analysis
    • 11.4.3. Europe by Country Sales Analysis
    • 11.4.4. United Kingdom Sales Analysis
    • 11.4.5. France Sales Analysis
    • 11.4.6. Germany Sales Analysis
    • 11.4.7. Italy Sales Analysis
    • 11.4.8. Russia Sales Analysis
    • 11.4.9. Rest Of Europe Sales Analysis
  • 11.5. Asia Pacific Sales Analysis
    • 11.5.1. Overview, Historic and Forecast Sales Analysis
    • 11.5.2. Asia Pacific by Segment Sales Analysis
    • 11.5.3. Asia Pacific by Country Sales Analysis
    • 11.5.4. China Sales Analysis
    • 11.5.5. India Sales Analysis
    • 11.5.6. Japan Sales Analysis
    • 11.5.7. South Korea Sales Analysis
    • 11.5.8. Australia Sales Analysis
    • 11.5.9. Rest Of Asia Pacific Sales Analysis
  • 11.6. Latin America Sales Analysis
    • 11.6.1. Overview, Historic and Forecast Sales Analysis
    • 11.6.2. Latin America by Segment Sales Analysis
    • 11.6.3. Latin America by Country Sales Analysis
    • 11.6.4. Brazil Sales Analysis
    • 11.6.5. Argentina Sales Analysis
    • 11.6.6. Peru Sales Analysis
    • 11.6.7. Chile Sales Analysis
    • 11.6.8. Rest of Latin America Sales Analysis
  • 11.7. Middle East & Africa Sales Analysis
    • 11.7.1. Overview, Historic and Forecast Sales Analysis
    • 11.7.2. Middle East & Africa by Segment Sales Analysis
    • 11.7.3. Middle East & Africa by Country Sales Analysis
    • 11.7.4. Saudi Arabia Sales Analysis
    • 11.7.5. UAE Sales Analysis
    • 11.7.6. Israel Sales Analysis
    • 11.7.7. South Africa Sales Analysis
    • 11.7.8. Rest Of Middle East And Africa Sales Analysis

12 . COMPETITIVE LANDSCAPE OF THE INFLUENZA VACCINE COMPANIES

  • 12.1. Influenza Vaccine Market Competition
  • 12.2. Partnership/Collaboration/Agreement
  • 12.3. Merger And Acquisitions
  • 12.4. New Product Launch
  • 12.5. Other Developments

13 . COMPANY PROFILES OF INFLUENZA VACCINE INDUSTRY

  • 13.1. Company Share Analysis
  • 13.2. Market Concentration Rate
  • 13.3. GSK plc
    • 13.3.1. Company Overview
    • 13.3.2. Company Revenue
    • 13.3.3. Products
    • 13.3.4. Recent Developments
  • 13.4. AstraZeneca
    • 13.4.1. Company Overview
    • 13.4.2. Company Revenue
    • 13.4.3. Products
    • 13.4.4. Recent Developments
  • 13.5. SINOVAC
    • 13.5.1. Company Overview
    • 13.5.2. Company Revenue
    • 13.5.3. Products
    • 13.5.4. Recent Developments
  • 13.6. Pfizer Inc
    • 13.6.1. Company Overview
    • 13.6.2. Company Revenue
    • 13.6.3. Products
    • 13.6.4. Recent Developments
  • 13.7. Vaxess Technologies Inc
    • 13.7.1. Company Overview
    • 13.7.2. Company Revenue
    • 13.7.3. Products
    • 13.7.4. Recent Developments
  • 13.8. CSL Limited
    • 13.8.1. Company Overview
    • 13.8.2. Company Revenue
    • 13.8.3. Products
    • 13.8.4. Recent Developments
  • 13.9. EMERGENT
    • 13.9.1. Company Overview
    • 13.9.2. Company Revenue
    • 13.9.3. Products
    • 13.9.4. Recent Developments
  • 13.10. Merck & Co. Inc.
    • 13.10.1. Company Overview
    • 13.10.2. Company Revenue
    • 13.10.3. Products
    • 13.10.4. Recent Developments
  • 13.11. Viatris Inc.
    • 13.11.1. Company Overview
    • 13.11.2. Company Revenue
    • 13.11.3. Products
    • 13.11.4. Recent Developments
  • 13.12. OSIVAX
    • 13.12.1. Company Overview
    • 13.12.2. Company Revenue
    • 13.12.3. Products
    • 13.12.4. Recent Developments
  • 13.13. EMERGEX VACCINES
    • 13.13.1. Company Overview
    • 13.13.2. Company Revenue
    • 13.13.3. Products
    • 13.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Vaccine Type (USD MN)
  • Inactivated Market Sales by Geography (USD MN)
  • Live Attenuated Market Sales by Geography (USD MN)
  • Analysis Market by Indication (USD MN)
  • Quadrivalent Market Sales by Geography (USD MN)
  • Trivalent Market Sales by Geography (USD MN)
  • Analysis by Age Group (USD MN)
  • Pediatric Market Sales by Geography (USD MN)
  • Adult Market Sales by Geography (USD MN)
  • Analysis by Route Of Administration (USD MN)
  • Injection Market Sales by Geography (USD MN)
  • Nasal Spray Market Sales by Geography (USD MN)
  • Analysis by Distribution Channel (USD MN)
  • Hospitals & Pharmacies Market Sales by Geography (USD MN)
  • Government & Institutional Supply Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Influenza Vaccine Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Influenza Vaccine Report
  • Market Research Process
  • Market Research Methodology
  • Global Influenza Vaccine Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Vaccine Type
  • Market Attractiveness Analysis by Indication
  • Market Attractiveness Analysis by Age Group
  • Market Attractiveness Analysis by Route Of Administration
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Vaccine Type (USD MN)
  • Inactivated Market Sales by Geography (USD MN)
  • Live Attenuated Market Sales by Geography (USD MN)
  • Global Market Analysis by Indication (USD MN)
  • Quadrivalent Market Sales by Geography (USD MN)
  • Trivalent Market Sales by Geography (USD MN)
  • Global Market Analysis by Age Group (USD MN)
  • Pediatric Market Sales by Geography (USD MN)
  • Adult Market Sales by Geography (USD MN)
  • Global Market Analysis by Route Of Administration (USD MN)
  • Injection Market Sales by Geography (USD MN)
  • Nasal Spray Market Sales by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Hospitals & Pharmacies Market Sales by Geography (USD MN)
  • Government & Institutional Supply Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.